Bilcare Ltd., service provider to the pharmaceutical companies spanning across their value chain from drug discovery to market, has registered a 38 per cent rise in its net profit at Rs 16.34 crore during the quarter ended September 30, 2007. Its net profit has increased by 38 per cent to Rs 16.34 crore from Rs 11.82 crore in the same period of last year.

Whereas company's, net sales went up by 30 per cent to Rs 102.28 crore from Rs 78.54 crore in the corresponding period of last year. Its EPS has increased to Rs 10.71 on enhance equity capital from Rs 8.32 in the last period.

This resulted in an EBITDA of Rs 31.03 cr. as against Rs 21.96 cr in the corresponding quarter of the previous year, registering a growth of 41 per cent. The consolidated revenue for the second quarter of FY 2008 stood at Rs.142.72 cr. This resulted in better consolidated earnings before interest depreciation and tax (EBITDA) of Rs.36.01 cr. and a net profit of Rs.19.07 cr. For the half year ended September 30, 2007, the net sales increased by 29 per cent to Rs 195.98 cr from Rs 151.73 cr in the corresponding quarter of the previous year.

"Our Clinical trial service and education business has started showing results, in the ensuing quarters, we would further expand and invest in this space in India and our foreign subsidiaries" said, Mohan Bhandari, chairman Bilcare Ltd.